Switzerland-based Actelion, developer of two approved pulmonary arterial hypertension (PAH) drugs Opsumit (macitentan) and, more recently, Uptravi (selexipag), announced…
Magdalena Kegel
Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Magdalena Kegel
Right ventricular dysfunction is intimately linked to pulmonary hypertension (PH). Since the dynamics of the two ventricles of the heart are…
Sildenafil (Revatio) — a phosphodiesterase type-5 inhibitor developed by Pfizer – is approved for the treatment of pulmonary arterial hypertension (PAH) in adults. Two large international…